Late-onset noninfectious pulmonary complications after allogeneic peripheral blood stem cell transplantation.
- Author:
Yi-Zhuo ZHANG
1
;
Chun-Ji GAO
;
Bo-Long ZHANG
;
Wan-Ming DA
;
Xiao-Pin HAN
;
Hong-Hua LI
;
Yu JING
;
Wen-Rong HUANG
;
Jian BO
;
Shu-Hong WANG
;
Hai-Yan ZHU
;
Hai-Jie JIN
;
Li YU
Author Information
1. Department of Hematology, PLA General Hospital, Beijing 100853, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Cyclosporine;
therapeutic use;
Female;
Graft vs Host Disease;
prevention & control;
Humans;
Incidence;
Leukemia;
therapy;
Lung Diseases, Interstitial;
classification;
drug therapy;
etiology;
Male;
Peripheral Blood Stem Cell Transplantation;
adverse effects;
Prednisone;
therapeutic use;
Retrospective Studies;
Risk Factors;
Transplantation, Homologous
- From:
Journal of Experimental Hematology
2007;15(3):632-635
- CountryChina
- Language:Chinese
-
Abstract:
The aim of study was to explore the incidence, risk factors, outcome and efficacious treatment of late-onset noninfectious pulmonary complications (LNIPC) after allogeneic peripheral blood stem cell transplantation (allo-PBSCT). Seventy patients received allo-PBSCT were analyzed retrospectively. The results showed that 9 out of 63 patients surviving more than 3 months occurred late-onset noninfectious pulmonary complications (14.3%). Five out of the 9 patients developed secondary pulmonary infections. In 4 patients, LNIPC caused death directly. Advanced stage of disease at transplantation and extensive chronic graft-versus-host disease (GVHD) happened in association with LNIPC. However, other transplantation-related factors including age at transplantation, gender of patient, conditioning regimen, HLA matching and GVHD prophylaxis were not significantly correlated with the incidence of LNIPC. It is concluded that performing pulmonary function test (PFT) and thoracic computer tomography should be taken routinely after transplantation. Most patients who get correct and early diagnosis for LNIPC will show a positive response to prednisone with or without CsA.
